Crestline Management LP Increases Position in Liquidia Co. (NASDAQ:LQDA)

Crestline Management LP increased its stake in shares of Liquidia Co. (NASDAQ:LQDA) by 69.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 83,305 shares of the company’s stock after buying an additional 34,246 shares during the period. Crestline Management LP’s holdings in Liquidia were worth $980,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LQDA. Steward Partners Investment Advisory LLC purchased a new stake in shares of Liquidia during the 4th quarter worth approximately $59,000. Summit Investment Advisors Inc. boosted its position in Liquidia by 35.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after purchasing an additional 1,719 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in Liquidia in the fourth quarter valued at $154,000. Bayesian Capital Management LP purchased a new position in shares of Liquidia in the fourth quarter valued at $163,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Liquidia during the 4th quarter worth $169,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, March 20th. Needham & Company LLC restated a “buy” rating and set a $25.00 price objective on shares of Liquidia in a research report on Thursday, April 10th. Finally, Scotiabank reiterated an “outperform” rating on shares of Liquidia in a report on Monday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $26.88.

Insider Buying and Selling

In other news, General Counsel Russell Schundler sold 5,964 shares of Liquidia stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $80,931.48. Following the transaction, the general counsel now directly owns 570,301 shares of the company’s stock, valued at $7,738,984.57. The trade was a 1.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the sale, the chief executive officer now directly owns 1,006,420 shares of the company’s stock, valued at approximately $13,657,119.40. This trade represents a 1.38 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,138 shares of company stock valued at $450,233. Insiders own 26.50% of the company’s stock.

Liquidia Stock Performance

Shares of LQDA opened at $15.35 on Friday. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $16.81. The stock has a fifty day moving average of $14.25 and a two-hundred day moving average of $13.12. The company has a market capitalization of $1.31 billion, a PE ratio of -9.42 and a beta of 0.24.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, equities research analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).